Recent Publications

• Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA vaccines for COVID-19 from Moderna and Pfizer/BioNtech
  R McMurry et al, MDRXIV, February 27, 2021
  
  We retrospectively compared the clinical notes of 31,029 individuals who received at least one dose of the Pfizer/BioNTech or Moderna mRNA vaccine to those of 30,933 unvaccinated individuals who were propensity matched by demographics, residential location, and history of prior SARS-CoV-2 testing. We find that vaccinated and unvaccinated individuals were seen in the clinic at similar rates within 21 days of the first or second actual or assigned vaccination date.
• Minimizing loss of life in Covid-19 in a 100 day period in the U.S.A. by personalized-dose vaccination and distribution of a limited vaccine supply
  P Hunziker, MEDRXIV< February 28, 2021
  
  Rapid reduction of Covid-19 case and death rate in the USA in 100 days with a limited vaccine supply is best achieved when personalized, age-tailored dosing for highly effective vaccines is used, according to this vaccination strategy model parameterized to U.S. demographics, Covid-19 transmission and vaccine characteristics. An 'elderly first' approach costs more lives, even in the elderly.
• Organoids: A New Model for SARS-CoV-2 Translational Research.
  Yu Jin, et al. International journal of stem cells 2021 2 0.
  
• Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants.
  Su Shan, et al. Emerging microbes & infections 2021 2 0. 1-7
  
• Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
  Shukla Ashwin Kumar, et al. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 2021 2 0.
  
• Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers.
  Nooraei Saghi, et al. Journal of nanobiotechnology 2021 2 0. (1) 59
  
• Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors.
  Brosey Chris A, et al. Progress in biophysics and molecular biology 2021 2 0.
  
• SARS-CoV-2 Vaccines
  CB Creech et al, JAMA, February 26, 2021
  
  This JAMA Insights clinical review explains different approaches to SARS-CoV-2 vaccine development, including inactivated and protein subunit, viral vector, and mRNA immunization strategies, and summarizes safety and efficacy data for global products authorized for use or in later-stage clinical trials.
• Covid-19 vaccine hesitancy among ethnic minority groups
  MS Razai et al, BMJ, February 26, 2021
  
  The most common reasons for hesitancy are concerns about side effects and the long term effects on health, and lack of trust in vaccines, particularly among black respondents. Some have capitalized on these concerns to spread misinformation, adding to the historical mistrust of government and public health bodies that runs deep in some ethnic minority groups.
• Covid-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel, shows peer reviewed study
  J Wise, BMJ, February 25,2021
  
• Monitoring social distancing under various low light conditions with deep learning and a single motionless time of flight camera.
  Rahim Adina, et al. PloS one 2021 0 0. (2) e0247440
  
• Evaluating the Traditional Chinese Medicine (TCM) Officially Recommended in China for COVID-19 Using Ontology-Based Side-Effect Prediction Framework (OSPF) and Deep Learning.
  Wang Zeheng, et al. Journal of ethnopharmacology 2021 2 0. 113957
  
• A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research.
  Rihn Suzannah J, et al. PLoS biology 2021 2 0. (2) e3001091
  
• Foreword - The importance of a healthy microbiota in the era of COVID-19.
  Venema Koen, et al. Beneficial microbes 2021 2 0. (1) 1-3
  
• Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant.
  Lee Cheryl Yi-Pin, et al. Clinical & translational immunology 2021 0 0. (2) e1241
  
• Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil.
  da Silva Francisco Ronaldo, et al. Virus research 2021 2 0. 198345
  
• Protection against COVID-19 in African population: Immunology, genetics, and malaria clues for therapeutic targets.
  Altable Marcos, et al. Virus research 2021 2 0. 198347
  
• A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs.
  Routhu Nanda Kishore, et al. Immunity 2021 2 0.
  
• Polyvaccine: joining the links in the cascade of type 1 diabetes.
  Desai Shivani, et al. Clinical and experimental vaccine research 2021 1 0. (1) 1-5
  
• Estimation of Undetected Symptomatic and Asymptomatic cases of COVID-19 Infection and prediction of its spread in USA.
  Mahajan Ashutosh, et al. Journal of medical virology 2021 2 0.